1 / 78

Asthma

Asthma. Ping-Wei Chen Dr. Sarah McPherson. Epidemiology. 8.4% adult prevalence in Canada (2000) Most common during childhood At least 12% Canadian children Prevalence increasing 1979 – 2.3 per cent 1988 – 4.9 per cent 1994 – 6.1 per cent Large economic burden

tekli
Download Presentation

Asthma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Asthma Ping-Wei Chen Dr. Sarah McPherson

  2. Epidemiology • 8.4% adult prevalence in Canada (2000) • Most common during childhood • At least 12% Canadian children • Prevalence increasing • 1979 – 2.3 per cent • 1988 – 4.9 per cent • 1994 – 6.1 per cent • Large economic burden • $12 billion spent on asthma (1993) • Estimated ¼ costs spent on acute asthma exacerbations

  3. Epidemiology • ED Visits • 146,000 ED Visits in Canada(1994) • 105,813 ED Visits in Alberta (Apr’99 – Mar’05) • Rowe B, et al. 2009 • Females • Aboriginal • Welfare/Government subsidized • CDC • Non-hispanic African Americans • Children 0-4 years old

  4. Pathophysiology • Bronchial Hyperreactivity • Bronchoconstriction response to various stimuli • Allergic Airway Inflammation • IgE mediated response to allergens • cell release of preformed mediators (histamine) • production of other cytokines (eg: prostaglandins, leukotrienes, ILs) • recruitment of other inflammatory cells Airway inflammation, Bronchoconstriction, Airway edema

  5. Pathophysiology • Eosinophils are the major effector cells • Release of preformed mediators (major basic protein, cationic protein, leukotrienes) • Production of inflammatory mediators (leukotrienes) • Neutrophils, Basophils, Macrophages have smaller role

  6. Pathology • Airway Remodelling • distinct to chronic asthma • airway edema/cellular infiltrates • epithelia damage • hypertrophy/hyperplasia smooth muscle layer • thickening of epithelial basement membrane • enlargement of mucus secreting apparatus • Diffuse Airway Involvement • large airways to airways <2mm in diameter

  7. Clinical Presentation • Cough, Dyspnea, Wheeze, Chest tightness • nocturnal worsening common • poor correlation of symptoms with airway obstruction (as per PFTs) • Difficulty with expiration > inspiration • a variable intrathoracic obstruction

  8. Clinical Presentation • Early Asthmatic Response • from release of preformed mediators • usually resolves within an hour • responds to mast cell stabilizers (β-agonists) • Late Asthmatic Response • result of cytokine generation and recruitment of inflammatory cells • clinically, 4-6 hours later • responds to anti-inflammatory therapy (corticosteroids, LT antagonists)

  9. Clinical Presentation • Gradual Onset • Mainly eosinophilic inflammation • Progression over hours to days • Less responsive to treatment • 80% deaths but preventable • Sudden Onset • Mainly neutrophilic • Progression <2 hours • massive allergen exposure/emotion • Rapid response to therapy

  10. Clinical Assessment

  11. Clinical Assessment • Clinical findings correlate poorly with severity of airway obstruction • Tachypnea (RR>40) • Accessory muscle use • Tachycardia (HR >120bpm) • Pulsus paradoxus • Upright position/inability to lie supine • Sweating • Difficulty finishing sentences • Cyanosis • Decreased LOC • “Quiet chest” Aldington S, Beasley R. Asthma exacerbations · 5: Assessment and management of severe asthma in adults in hospital. Thorax 2007;62:447-458.

  12. Lung Volumes

  13. Pulmonary Function Testing • Flow Rates • Forced Vital Capacity (FVC) • Forced Expiratory Volume in 1 second (FEV1) • Maximum Midexpiratory Flow Rate (MMFR) • “Normal” Standards/Predicted Values • Large numbers of non-smoking controls • Regression equations (age, height) • 95% confidence intervals VS >80% predicted

  14. Pulmonary Function Testing • Flow-Volume Loops

  15. Objective Measurements

  16. PEFR VS FEV1 • Aggarwal AN, Gupta D, Jindal SK. The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. Chest. 2006 Nov;130(5):1454-61. • Cross-sectional, retrospective study • 6,167 adult patients showing obstructive pattern on spirometry over a 6-year period • “we found that in patients with severe airway obstruction (FEV1 < 40% of predicted), PEF% overestimated FEV1 %, whereas exactly the opposite happened in patients with less severe airway obstruction”

  17. PEFR VS FEV1

  18. Diagnostic Strategies • Pulmonary Function Testing • Initially, then 30-60 mins after initial treatment • NOT indicated in initial assessment of life-threatening asthma exacerbation (Evidence D) National Asthma Education and Prevention Program: Expert Panel Report III. 2007

  19. Diagnostic Strategies • Arterial Blood Gas • Rarely indicated • Consider in: • Inability to obtain O2 sat • Severe distress • Perplexing clinical course/Non-response to treatment • If done: • PaCO2 usually low (normal to high – severe airflow restriction, impending respiratory failure)

  20. Diagnostic Strategies • Pulse oximetry • Useful to assess both severity and improvement with treatment • Boychuk R. et al. Correlation of initial emergency department pulse oximetry values in asthma severity classes (steps) with the risk of hospitalization. Am J Emerg Med. 2006; 24(1)48-52. • “The presenting OSAT is the dominant initial predictor of hospitalization”

  21. Diagnostic Strategies • Blood Tests • Rarely indicated • CBC: • ↑WBC (stress response/steroids/epinephrine) • Theophylline level • CXRay • Not routinely indicated • Consider in: suspected complicating process • Pneumonia, PTX, pneumomediastinum, CHF, lobar atelectasis

  22. Diagnostic Strategies • Cardiac Monitoring • Not routinely indicated • indicated for: • severe hypoxemia • comorbid patients • Age >50

  23. Case • 23yo female • 1 week hx of increasing SOB, wheezing, nocturnal cough • Med Hx: asthma • Meds: ventolin, symbicort • Vitals: 36.7oC, 115bpm, RR36, 102/70, 93% RAO2 • Short sentences, SCM use • Moderate A/E bilat, expiratory wheezes

  24. Management • Oxygen therapy • O2 sats >90% in all patients, • >95% in pregnant or CV comorbid patients • Short-Acting β-agonist (Evidence A) • Ventolin • MDI/spacer: 4-8 puffs q20mins X 3, then q1-4 hours PRN • Nebulizer: 2.5mg-5mg q20mins X 3, then q1-4 hours PRN • Continuous Neb: 10mg-15mg/hour • IV: 4µg/kg for 2-5 mins, then 0.1µg -0.2µg/kg/min National Asthma Education and Prevention Program: Expert Panel Report III. 2007

  25. MDI versus Nebulizer • No significant difference • Hospital admission rate (RR 0.97, 95% CI 0.63 to 1.49) • Time spent in ED (MD 0.02 hours, 95% CI -0.4 to 0.44) • PEFR/FEV1 • FEV1 <30% predicted (MD -1.6% predicted, CI -7.69 to 4.49)

  26. MDI versus Nebulizer • No significant difference • Number of participants given steroids • Change in respiratory rate • Pulse rate

  27. MDI versus Nebulizer Dolovich et al. 2005. • “Both the nebulizer and MDI with spacer/holding chamber are appropriate for the delivery of short-acting β2 -agonists in the ED. Quality of evidence: good”

  28. Management • Ipratropium Bromide (Evidence A) • MDI/spacer: 4-8 puffs q20mins X 3, then as needed • Nebulizer: 0.25mg - 0.5mg q20mins X3, then as needed

  29. Management • 32 RCTs (16 adult, 16 peds) • 3611 patients • Results: • Decreased hospital admission (RR 0.68, 95% CI 0.53-0.86) • NNT = 14 • Larger decrease in: most severe asthma, treatment with multiple doses • Increased PEFR (WMD -44.18, 95% CI -57.72 to -30.84) • Larger increase in treatment with muiltiple doses

  30. Management • Corticosteroids • Oral • Prednisone 40mg-60mg q6-8h until improved, then OD X 5-10 days • IV • Methylprednisolone 60mg-125mg q6-8h until improved • Hydrocortisone 200mg-500mg q6-8h until improved • Fiel SB. et al. Systemic corticosteroid therapy in acute asthma exacerbations. J Asthma. 2006;43:321-331 • “no clear evidence supports any one route of systemic corticosteroid administration over another”

  31. Management • Corticosteroids • 12 studies, 863 patients • Administration of IV/IM/PO steroids <1hr after presentation • Reduced hospital admissions (NNT =8); • NNT = 5 when baseline admission rate >40% (ie:severe asthma) • Improved PEFR (persistent heterogeneity) • SMD 0.54; 95% CI 0.01 to 1.1

  32. Management • Corticosteroids • 6 studies, 374 patients • PO/IM corticosteroids on discharge following acute exacerbation of asthma • Fewer relapses to addition care at 7-10 days (RR 0.38, 95% CI 0.20 to 0.74, NNT = 9) • Fewer relapse requiring hospitalizations (RR 0.35, 95% CI 0.13 to 0.95) • Decreased use of β-agonist (MD -3.3 use/day, 95% CI -5.6 to -1.0)

  33. Management • Corticosteroids • Side effects: • Reporting uncommon • “similar in frequency”, “rare” • Nausea (N=2, OR 0.48; 95% CI 0.1 to 2.4) • Tremor (N=4, OR 0.82; 95% CI 0.45 to 1.48) • Headache (N=2, OR 1.04; 95% CI 0.01 to 1.1)

  34. Case • 30yo male transferred from Brooks Hospital • Week long hx of increasing SOB, wheezing, nocturnal cough • Med Hx: asthma (always worse in spring) • Meds: Ventolin, Symbicort, Singulair • Vitals: 37.2oC, RR48, 122bpm, 130/86, 90% on 10L O2 by mask • Sitting upright, anxious, SCM/SS indrawing • Poor A/E, intermittent wheezing

  35. Management • Epinephrine • IV for severe/nonresponsive: • 200µg-1000µg 1:10,000 solution over 5 mins • 1µg-20µg/min infusion if response to bolus • SC for inability to inhale • 0.2mL-0.5mL 1:1000 solution q20mins X 3 doses maximum

  36. Management • Epinephrine • Not a lot of evidence for efficacy… • Plint A. et al. The efficacy of nebulized racemic epinephrine in children with acute asthma: a randomized, double blind trial. Acad Emerg Med. 2000;7(10):1097-1103 • Prospective, randomized, double-blind study • 121 patients • Primary Outcome: Pulmonary Index Score (PIS) • Secondary Outcomes: change in O2 sat, length of ED stay, return visits • No difference: change in PIS, O2 sat, O2 requirement, ED stay length, hospital admissions, length of hospital stay

  37. Management • Epinephrine • Not a lot of evidence for efficacy… • Abroug F. et al. A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma. Intensive Care Med. 1995;21:18-23 • Prospective, randomized, double-blind study • 22 ICU patients • Primary outcome: PEFR • No statistical difference in PEFR, HR, PaCO2, cardiac rhythm • Effect of Salbutamol on ↓RR greater

  38. Management • Magnesium • IV: 2g-3g over 5-10mins • Side effects: hypotension, respiratory depression, N/V, flushing • Indicated in severe asthma • Cochrane Review: Rowe et al. 2000 • 7 trials, 665 patients • Pooled study results show no significant difference • In severe subgroup: • Decreased hospital admissions (OR 0.10, 95% CI 0.04 to 0.27)

  39. Management • Magnesium: Nebulized VS Intravenous • Cochrane Review: Blitz et al. 2005 • No difference in rate of hospitalization • No difference in pulmonary function tests • In severe subgroup: • PFTs improved (SMD 0.55; 95% CI 0.12 to 0.98)

  40. Management • Methylxanthines • Not recommended (Evidence A) • National Asthma Education and Prevention Program: Expert Panel Report III. 2007 • Cochrane Review: Parameswaran et al. 2000 • No statistical signficance airflow outcomes • More palpitations/arrhythmias

  41. Management • Heliox • 60%-80% helium + 20%-40% oxygen • Consider heliox-driven β-agonist nebulization • Life-threatening exacerbation • Patients who remain severe after 1 hr intensive conventional therapy • Cochrane Review: Rodrigo et al. 2006 • 10 trials, 544 patients • No significant difference in PFTs, admissions to hospital • Significant difference in PFT (N = 3, SMD 0.61; 95% CI 0.21 to 1.00)

  42. Management • Leukotriene Receptor Antagonists • Zafirlukast: 160mg PO once • Montelukast: 7mg-14mg IV once • Camargo et al. 2003 • Randomized, double-blind, pilot study • 194 patients • 7mg or 14 mg Montelukast IV versus placebo

  43. Management

  44. Management • Camargo et al. 2003 • Results • Improved FEV1 at 10 mins, up to 2 hours • Fewer β-agonist nebulizations • No effect: • Hospitalizations • Unscheduled, asthma related visits to ED • Doctor visits • Need for rescue corticosteroids in 14 days after discharge

  45. Management • Leukotriene Receptor Antagonists • National Asthma Education and Prevention Program: Expert Panel Report III. 2007 • Evidence D • “Intravenous LRTAs could provide another pathway to rapid bronchodilation during impending respiratory failure”

  46. Management • Antibiotics • National Asthma Education and Prevention Program: Expert Panel Report III. 2007 • “not generally recommended for the treatment of acute asthma exacerbations except as needed for comorbid conditions” (Evidence B) • Fever, purulent sputum, pneumonia • Cochrane Review: Graham et al. 2001 (update 2005) • 2 studies, 97 patients • “not enough evidence on whether antibiotics given to people with acute asthma (without evidence of infection) is effective”

  47. Status Asthmaticus • Severe bronchospasm that does not respond to aggressive therapies within 30-60 mins • “Throw everything at it” • IV β-agonist • Epinephrine • Magnesium • Heliox • Leukotriene inhibitors • NIPPV • Intubation

  48. Disposition • Good Response – PFTs >70% • Home • Incomplete Response – PFTs >50% but <70% • Individualized decision • ?severe cough, wheeze, SOB, lack of self care admit • ?Risk factors for death from asthma  admit • Poor Response – PFTs <50% • Admit

  49. Chronic Obstructive Pulmonary Disease

  50. Epidemiology • Prevalence in Canada (GOLD Stage ≥2) • Men 9.3%, Women 7.3% (2007) • Increasing prevalence with age • Pooled OR 1.94, 95% CI 1.80 to 2.10 per 10 years of life • Significant economic burden Buist et al. 2007. Lancet; 370:741-750.

More Related